AOC 1001

Avidity Biosciences, Inc. · Phase 2 active Small molecule

At a glance

Generic name	AOC 1001
Sponsor	Avidity Biosciences, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients (PHASE1, PHASE2)
Global Open-Label Extension Study of Del-desiran for the Treatment of DM1 (PHASE3)
Global Study of Del-desiran for the Treatment of DM1 (PHASE3)
Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AOC 1001 CI brief — competitive landscape report
AOC 1001 updates RSS · CI watch RSS
Avidity Biosciences, Inc. portfolio CI